Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders of pregnancy, gestational diabetes, have a preterm birth or cesarean ...

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...

However, a new class of medications, GLP-1 agonists, originally designed for diabetes and obesity management, shows promise as a revolutionary tool in addiction treatment. GLP-1, or glucagon-like ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may increase the risk of pulmonary aspiration among patients undergoing surgery ...

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

The analysis included 98,147 GLP-1 RA users and approximately 2.49 million DPP-4i users, with a median follow-up ranging from 1.8 to 3 years. HealthDay News — Glucagon-like peptide 1 receptor ...